Trials / Not Yet Recruiting
Not Yet RecruitingNCT07409805
YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment
Evaluation of Safety and Efficacy of YMN-136 Vaccine in Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment: A Prospective Phase I Clinical Study
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- West China Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | YMN-136 Vaccine | The YMN-136 vaccine will be administered according to the dose level assigned to each patient. Approximately every 3 weeks, the vaccine will be administered via intramuscular injection into the single upper arm, with 4 doses for prime immunization. |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2028-02-01
- Completion
- 2028-03-01
- First posted
- 2026-02-13
- Last updated
- 2026-02-13
Source: ClinicalTrials.gov record NCT07409805. Inclusion in this directory is not an endorsement.